CureVac (CVAC) Investor Presentation summary

Strategic transformation and financial position

• Streamlined operations with a 30% workforce reduction and cost savings exceeding 30% from 2025, including €25M in personnel cost reduction.

• Cash position of €550.9M as of September 30, 2024, with a secured runway into 2028.

• Received €400M upfront from GSK collaboration, with additional €80.4M from contract liabilities.

• Deprioritized commercial manufacturing to focus on clinical trial supply, leading to partial impairment of GMP IV.

• Closed all COVID-19 vaccine-related commitments and arbitrations, with no further payments due.

Pipeline expansion and R&D focus

• Advancing off-the-shelf and personalized cancer vaccines, with glioblastoma trials showing promising T cell responses in 77% of evaluable patients.

• New shared-antigen lung cancer program to start clinical trials in H2 2025; personalized cancer vaccine candidate expected in H2 2026.

• Uropathogenic E. coli (UPEC) vaccine program initiated for urinary tract infections, showing superior preclinical immunogenicity.

• Infectious disease programs for influenza, avian flu, and COVID-19 fully out-licensed to GSK, with Phase 3 flu trial expected in 2025.

• Ongoing discovery for additional oncology and infectious disease indications throughout 2025-2026.

Technology and manufacturing capabilities

• Proprietary mRNA backbone and advanced LNP delivery systems enable robust immune responses at low doses.

• The RNA PrinterⓇ provides automated, GMP-grade mRNA manufacturing for rapid clinical and personalized supply.

• LNP technology offers thermostability for over 12 months at refrigerator temperature and targeted biodistribution to reduce off-target effects.

• Manufacturing focus shifted to clinical trial supply, leveraging scalable in-house and automated systems.